There is no cure, or treatment, for dry age-related macular degeneration (AMD) at this time. Individuals diagnosed with advanced wet AMD can receive injections of therapeutic drugs in the eye to slow the progression of vision loss. Patients that are able to receive therapeutic injections will seek treatment with their eye doctor.
Approximately ninety-five percent of AMD patients are diagnosed with dry AMD. Researchers at the Retina Foundation are working diligently to find treatments for these individuals. Funding for this research is a crucial part of discovering treatments. Our AMD research is supported by individuals, foundations, and pharmaceutical/biotechnology corporations.
If you have any questions about clinical trials being conducted at the Retina Foundation, or would like more information, please contact our AMD clinical research staff at firstname.lastname@example.org.
AMD CLINICAL STUDIES WE ARE CURRENTLY ENROLLING FOR:
For detailed information go to clinicaltrials.gov NCT#: 05019521
Study Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
For detailed information go to clinicaltrials.gov NCT#: 03972709
Study Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
For detailed information go to clinicaltrials.gov NCT#: 04615325
Study Title: A Phase Ia Multicenter, Open -Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogencity of Intravitreal Injections of RO7303359 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
For detailed information go to clinicaltrials.gov NCT#: 04566445
Study Title: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
For detailed information go to clinicaltrials.gov NCT#: 03364153
Study Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
For detailed information go to clinicaltrials.gov NCT#: 03815825
Study Title: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Related ArticlesGene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News Chance Encounter Leads to Early Diagnosis and Treatment for Kate Age-Related Macular Degeneration Happenings at the Foundation An iPhone App to Monitor Eye Disease Developing a Treatment for Age-Related Macular Degeneration – Video Update